Your browser doesn't support javascript.
loading
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model.
Garofalo, Mariangela; Wieczorek, Magdalena; Anders, Ines; Staniszewska, Monika; Lazniewski, Michal; Prygiel, Marta; Zasada, Aleksandra Anna; Szczepinska, Teresa; Plewczynski, Dariusz; Salmaso, Stefano; Caliceti, Paolo; Cerullo, Vincenzo; Alemany, Ramon; Rinner, Beate; Pancer, Katarzyna; Kuryk, Lukasz.
Affiliation
  • Garofalo M; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Wieczorek M; Department of Virology, National Institute of Public Health, National Institute of Hygiene (NIH) - National Research Institute, Warsaw, Poland.
  • Anders I; Division of Biomedical Research, Medical University of Graz, Graz, Austria.
  • Staniszewska M; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warsaw, Poland.
  • Lazniewski M; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warsaw, Poland.
  • Prygiel M; Department of Bacteriology and Biocontamination Control, National Institute of Public Health, National Institute of Hygiene (NIH) - National Research Institute, Warsaw, Poland.
  • Zasada AA; Departament of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene (NIH) - National Research Institute, Warsaw, Poland.
  • Szczepinska T; Departament of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene (NIH) - National Research Institute, Warsaw, Poland.
  • Plewczynski D; Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warsaw, Poland.
  • Salmaso S; Laboratory of Bioinformatics and Computational Genomics, Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland.
  • Caliceti P; Laboratory of Functional and Structural Genomics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
  • Cerullo V; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Alemany R; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Rinner B; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Pancer K; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Kuryk L; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Helsinki, Finland.
Front Oncol ; 13: 1259314, 2023.
Article in En | MEDLINE | ID: mdl-38053658

Full text: 1 Database: MEDLINE Language: En Journal: Front Oncol Year: 2023 Type: Article Affiliation country: Italy

Full text: 1 Database: MEDLINE Language: En Journal: Front Oncol Year: 2023 Type: Article Affiliation country: Italy